Increased expression of individual genes in whole blood is associated with late-stage lung cancer at and close to ...
Quality Of Life For Patients With Epithelial Ovarian Cancer
Parkin DM et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108
Ozols R et al. (2005) Epithelial ovarian cancer. In Principles and Practice of Gynecologic Oncology, 895–987 (Eds Hoskins W et al.) Philadelphia: Lippincott Williams & Wilkins
Boyd J (2003) Hereditary ovarian cancer: what we know. Gynecol Oncol 88 (Suppl): S8–S10
Goff BA et al. (2000) Ovarian carcinoma diagnosis. Cancer 89: 2068–2075
Goff BA et al. (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291: 2705–2712
Olson SH et al. (2001) Symptoms of ovarian cancer. Obstet Gynecol 98: 212–217
Stirling D et al. (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23: 5588–5596
Menon U et al. (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23: 7919–7926
Munoz KA et al. (1997) Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15: 3408–3415
Armstrong DK et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43
FIGO Staging Committee (1986) International Federation of Gynecology and Obstetrics Staging Announcement. Gynecol Oncol 25: 383–385
Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259
Bookman M (2006) GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract #5002]. J Clin Oncol
Taylor KL et al. (2004) Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 96: 1083–1094
Cella DF and Bonomi AE (1995) Measuring quality of life: 1995 update. Oncology (Williston Park) 9: 47–60
Ahlberg K et al. (2005) The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 42: 377–386
Bergmark K et al. (2002) Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 81: 443–450
Chan YM et al. (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9–16
Ell K et al. (2005) Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 23: 3052–3060
Fallowfield LJ et al. (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910–917
Frumovitz M et al. (2005) Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23: 7428–7436
Herbst RS et al.; American Society of Clinical Oncology (2006) Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 24: 190–205
Janda M et al. (2004) Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer 14: 875–881
Le T et al. (2003) Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv 58: 749–758
Gillette-Cloven N et al. (2001) Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 193: 626–632
Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505–1509
Ratliff CR et al. (1996) Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer 78: 2229–2235
Roos EJ et al. (2004) Quality of life after pelvic exenteration. Gynecol Oncol 93: 610–614
Taphoorn MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6: 937–944
Zhu L et al. (2005) Quality-of-life analysis in the management of endometrial cancer. Am J Obstet Gynecol 192: 1388–1390
Gordon AN et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of peglyated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3321–3322
Coenen M et al. (2000) Gemcitabine in platinum-paclitaxel resistant ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 19: a603
Freidlander M et al. (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9: 1343–1345
Lund B et al. (1994) Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530–1533
Rose PG et al. (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405–410
Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Cella DF et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570–579
Cull A et al. (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47–53
Greimel E et al. (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39: 1402–1408
Basen-Engquist K et al. (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19: 1809–1817
Stiggelbout AM and de Haes JC (2001) Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 19: 220–230
Calhoun EA et al. (2004) A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 93: 164–169
Sun CC et al. (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87: 118–128
Sun CC et al. (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13: 219–227
Graziottin A and Basson R (2004) Sexual dysfunction in women with premature menopause. Menopause 11: 766–777
Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
Loprinzi CL et al. (1998) Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16: 2377–2381
Barton D et al. (2002) Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 29: 33–40
Kimmick GG et al. (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12: 114–122
Bodurka D et al. (2005) Ovarian cancer: quality of life issues. Boca Raton: National Ovarian Cancer Coalition
Wenzel LB et al. (2002) Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 11: 142–153
Carmack Taylor CL et al. (2004) Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 22: 881–889
Penson RT et al. (2004) Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 94: 427–435
Stead ML et al. (2001) Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ 323: 836–837
Bodurka DCSC et al. (2005) Helping cancer patients with quality of life treatment decisions (audio CD). ACOG update 31: October 2005
Stewart DE et al. (2001) "What doesn't kill you makes you stronger": an ovarian cancer survivor survey. Gynecol Oncol 83: 537–542
Tabano M et al. (2002) Symptoms affecting quality of life in women with gynecologic cancer. Semin Oncol Nurs 18: 223–230
Wenzel L et al. (2005) Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (34): 94–98
Friedman LC and Kramer RM (2005) Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr (34): 83–86
Robson M et al. (2003) Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89: 281–287
Chi DS et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103: 559–564
Eisenkop SM and Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 82: 435–441
Pothuri B et al. (2003) Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 89: 306–313
Pothuri B et al. (2005) Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96: 330–334
Kim Y and Morrow GR (2003) Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 11: 171–177
Lindley CM et al. (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1: 331–340
O'Brien BJ et al. (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149: 296–302
Doherty KM (1993) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3: 113–119
Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18: 163–173
Oo TH and Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2: 196–201
Kris MG et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932–2947
Edwards SJ (2003) Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer. Semin Oncol Nurs 19: 19–39
Camp-Sorrell D (2000) Chemotherapy: toxicity management. In Cancer Nursing Principles and Practice, 444–486 (Eds Yarbro C et al.) Sudbury: Jones and Bartlett
Sweeney CW (2002) Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clin J Oncol Nurs 6: 163–166
Ocean AJ and Bahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12: 619–625
Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21: 439–451
Boling W et al. (2003) Health-related quality of life in gynecological oncology: instruments and psychometric properties. Int J Gynecol Cancer 13: 5–14
Carelle N et al. (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155–163
National Comprehensive Cancer Network (2006) Cancer- and treatment-related anemia. Cancer Practice Guidelines in Oncology, Version 1 [http://www.Nccn.Org] (accessed 28 November 2006)
Ludwig H and Strasser K (2001) Symptomatology of anemia. Semin Oncol 28: 7–14
Groopman JE and Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634
Holzner B et al. (2003) Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97: 1564–1572
Elit L et al. (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1: 149–156
Fry A et al. (2001) Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 10: 231–241
Norton TR et al. (2004) Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 22: 919–926
Ferrell B et al. (2003) Psychological well being and quality of life in ovarian cancer survivors. Cancer 98: 1061–1071
Howell D et al. (2003) Impact of ovarian cancer perceived by women. Cancer Nurs 26: 1–9
Hamilton AB (1999) Psychological aspects of ovarian cancer. Cancer Invest 17: 335–341
Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519–2529
Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1): S3–S11
Daugherty C et al. (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13: 1062–1072
Doyle C et al. (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19: 1266–1274
Horng S et al. (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347: 2134–2140
von Gruenigen VE and Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97: 638–644
Baile WF et al. (1999) Discussing disease progression and end-of-life decisions. Oncology (Williston Park) 13: 1021–1031; discussion 1031–1036, 1038
Chu C and Rubin SC (2004) Management of intestinal obstruction in the terminal patient and management of ascites. In Gynecologic Cancer: Controversies in Management, 727–741 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd
Whitworth MK et al. (2004) Doctor, does this mean I'm going to starve to death? J Clin Oncol 22: 199–201
Buckman R and Baile W (2004) Death and dying. In Gynecologic Cancer: Controversies in Management, 743–752 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd
Focus On Ovarian Cancer
National guidelines recommend primary surgery as the preferred initial treatment for advanced ovarian cancers despite studies showing less perioperative morbidity with neoadjuvant chemotherapy followed by surgery. High use of neoadjuvant chemotherapy in patients with advanced ovarian cancer has also been shown to lead to greater improvements in short-term mortality and equivalent gains in median overall survival compared with using this treatment infrequently.
Researchers from the UK Collaborative Trial of Ovarian Cancer Screening—the largest ovarian cancer screening trial to date—have concluded that general population screening does not provide significant reduction in ovarian or tubal cancer deaths. But that could change.
Results of a recent study show pathogenic variants are a common cause of breast cancer in Caribbean women, and that panel testing for multiple variants may be warranted.
We may be gaining clarity on a set of complex issues.
Radiotherapy used to treat local and regional rectal cancer was associated with an increased risk of a second gynecologic malignancy in a large, population-based cohort study. The findings may help guide treatment decisions for patients with rectal cancer.
Teams of investigators continue to evaluate the effects of NACT followed by interval cytoreductive surgery in advanced ovarian cancer. This is an update.
Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, laparoscopic adjustable gastric banding: All seem to reduce the risk of female-specific cancers in obese women, according to a recent study.
Here are the highlights of an ASCO systematic review-based guideline regarding testing for epithelial ovarian cancer.
Where a woman lives may be part of the risk mix that determines outcomes in epithelial ovarian cancer (EOC), say the investigators behind 2 related epidemiologic trials.
Breastfeeding can significantly lower a woman's risk of ovarian cancer, and the benefit may extend well beyond pregnancy.
Investigators from Johns Hopkins School of Medicine crunched data collected during 2 separate phases of the Affordable Care Act to assess possible differences in diagnosis and treatment.
A retrospective observational study examined the incidences and predictors of intraoperative capsule rupture in this group of patients.
True or false? Test your knowledge about ovarian cancer.
A prospective analysis found a slightly increased risk of ovarian cancer associated with genital powder use. The risk was somewhat higher among women with frequent use and an intact reproductive system.
A new study including data from a large cohort of women with mucinous ovarian carcinoma assesses the potential for novel and existing therapies to target this rare histotype.
What are the factors that stand between older women with ovarian cancer and potentially beneficial surgery?
This study explores factors associated with complications and survival among women with epithelial ovarian cancer who undergo primary debulking surgery.
A new study helps clarify the role of C-reactive protein, a marker of chronic inflammation, in the development of ovarian cancer.
Elena Ratner, MD, gynecologic oncologist and director of Yale's Sexuality, Intimacy, and Menopause cancer survivorship program discusses barriers to sexual healthcare among women being treated for gynecologic cancer.
A connection may exist between PTSD symptoms and a woman's likelihood of being diagnosed with ovarian cancer.
Aggressive, disease-targeted treatment for brain metastases may be warranted in women with BRCA-mutated EOC.
There has been a shift toward greater use of neoadjuvant chemotherapy in patients with advanced ovarian cancer. Is it the right choice?
A clearer view of some of the practical difficulties associated with centralizing care are emerging.
Results of a randomized, controlled clinical trial of patients with macroscopically complete advanced ovarian cancer resection and clinically negative lymph nodes cast doubt on the value of systematic lymphadenectomy.
True or False: Can you answer these questions correctly?
This analysis sheds light on the incidence of non–AIDS-defining gynecologic cancers in HIV-positive women at a time when effective treatments, and therefore greater life expectancies, have led to more cancers in this population.
A recent study with 20 years of follow-up supports earlier findings that the 5-year survival advantage seen among women with invasive epithelial ovarian cancer (EOC) and BRCA1/2 mutations decreases over time.
The more aggressive the cancer, the more likely it is that lifestyle factors like tobacco use may be associated with advanced disease.
Do physicians overestimate a woman's fitness for primary debulking surgery in the context of ovarian cancer?
Can you answer these questions correctly?
Simple cysts rarely if ever become malignant, but clinicians continue to recommend routine monitoring. Can we stop now?
Compared to other solid tumors, including colon and endometrial cancer, ovarian cancer puts patients at higher risk for VTE.
A purported reduction in breast cancer risk with risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers may be due to inappropriate data analyses.
We have information that may lead to more targeted management of patients with high-grade serous epithelial ovarian cancer.
A possible relationship between pregnancy loss and subsequent malignancies was assessed in a cohort of nearly 200,000 women.
These findings may lead to better interpretations of multigene panel testing in oncology practice.
Why do the forces that dictate long-term survival in epithelial ovarian cancer remain such a mystery?
Do you know the right answers to these questions about ovarian cancer?
These aren't easy conversations for healthcare providers to initiate, but for some women they're vital to the overall healing process.
These investigators developed a decision-analytic and cost-effectiveness model to compare salpingectomy and tubal ligation as means of permanent sterilization plus ovarian cancer risk reduction.
This gynecologic oncologist explains how little we really understand about ovarian cancer risk factors.
Don't overlook the importance of disease heterogeneity in epithelial ovarian cancer.
A notable aspect of this hypotheses-generating study is the magnitude of the mortality reduction with regular post-diagnosis use of aspirin and other NSAIDs.
A recent study found a significant decrease in overall survival among ovarian cancer patients unexpectedly admitted to the ICU after surgery.
Previous studies that examined the risk factors for certain ovarian cancers have produced inconsistent results. Here's what a new analysis determined.
Answer these questions to find out.
A recently identified serological marker considered the gold standard in detecting prior chlamydial infections was used to assess a possible relationship between ovarian cancer and this common infection.
We are gaining a better understanding of the relationship between ovarian and fallopian tube cancer.
In an analysis of 551 patients with serous stage IV ovarian cancer, those with metastases located only in the lymph nodes had better survival than those with pleural metastases or metastases in multiple sites.
The results of a new study suggest that tumor markers could serve as biopredictors of venous thromboembolism, opening the door to VTE prophylaxis in susceptible patients.
Do popular deli-counter meats, including ham, salami, and smoked sausages, increase the risk of certain cancers? Investigators in Italy, where the preparation of these meats has been raised to an art form, looked for answers.
A recent study matched cases of invasive epithelial ovarian cancer with cancer-free controls to assess the association between CA125 antigen and CA125 autoantibodies and how they may work together to provide earlier detection in at-risk women.
A woman whose paternal grandmother had ovarian cancer may have an elevated risk of that disease—and she and any sisters have a higher risk than their mother.
Quarterly Quiz: March 2018
A new study with whole-exome sequencing has substantially strengthened the evidence that ovarian carcinomas originate in the fallopian tubes. What are the implications for prevention, early detection, and treatment?
Long-term survival in women with epithelial ovarian cancer (EOC) has not increased in the last 25 years, despite better treatment options and improved clinical procedures. Progress in short-term survival rates is more indicative of better disease control than cure, and caution is needed when analyzing survival trends of early or advanced stage patients compared with both groups as a whole.
The findings of a recent study show that a rapid increase in neoadjuvant chemotherapy use in certain regions of the U.S. Was associated with reduced mortality within 3 years of diagnosis.
A possible association between menstrual pain and ovarian cancer risk has been investigated in the past, but these studies were inadequately powered to assess the association among various subtypes. This study shows a modest increase in ovarian cancer risk in women with severe menstrual pain.
Evidence from epidemiological studies suggest that different histological types of ovarian cancer have different risk factors. This is consistent with the hypotheses that different ovarian cancer subtypes have different origins.
This case highlights the natural history of ovarian cancer, the common treatment paradigms and decision-making processes, and reflects the heterogeneous biology of the disease.
Ovarian cancers are classified into epithelial, stromal, or germ cell cancers based on their putative cell of origin. This article focuses on epithelial ovarian cancer (EOC), which accounts for 90% of all ovarian cancer. Little is known about its early development.
Quarterly Quiz: December 2017
This prospective study provides data on a significant dose-response relationship between improved survival outcomes and increasing CD8+ TILs in high-grade serous, endometrioid, and mucinous ovarian cancers.
In a retrospective cohort study, three-quarters of HIV infected women with advanced gynecologic cancer did not receive NCCN guideline-adherent care and had lower survival than those who did.
If a physician is suspicious of ovarian cancer, referral to a gynecologic oncologist can help expedite diagnosis, staging, and surgery to help improve the patient's prognosis.
Despite recommendations against ovarian cancer screening in the general population, clinicians often provide screening to low/medium-risk women. And even among physicians who consider this strategy ineffective, patient requests may drive inappropriate screening.
While improvements in screening and detection have been made for gynecologic cancers--most notably cervical cancer--others, such as ovarian cancer, are diagnosed in the late stages of disease.
Machine learning, which helps find correlations in large data sets, is gaining ground in cancer treatment. John F. McDonald, PhD, explains why and shares his vision for the future of this technology in oncology.
Ovarian Cyst Removal
If an ovarian cyst is left untreated, it will usually resolve on its own. However, a solid or partially solid cyst may need to be evaluated by a lab to make sure it isn't cancerous. While most ovarian cysts don't need treatment, we may monitor your cyst and perform an ultrasound to determine whether you need surgery.
We may recommend surgical removal if a cyst:
If you experience severe ovary pain, you may have ovarian cyst torsion (a twisted ovary), which could cut off blood circulation to your ovary. If you experience twisted ovary symptoms, seek emergency care immediately to save your ovary.
Comments
Post a Comment